{"id":46983,"date":"2022-08-05T15:01:38","date_gmt":"2022-08-05T13:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/"},"modified":"2022-08-05T15:01:38","modified_gmt":"2022-08-05T13:01:38","slug":"guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/","title":{"rendered":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer"},"content":{"rendered":"<div>\n<p>\n<i>Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer<\/i>\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/5\/GuardantHealthLogo_TM_RGB-2C.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg\"><\/a><\/p>\n<p>PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests and real-world data will be presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022), hosted by the International Association for the Study of Lung Cancer, August 6-9 in Vienna, Austria. Among the 10 abstracts are oral presentations and posters highlighting the use of Guardant360<sup>\u2122<\/sup> to help physicians inform treatment decisions, GuardantOMNI<sup>\u2122<\/sup> to advance cancer therapy trials, and GuardantINFORM\u2122 for targeted drug development to improve outcomes for patients with lung cancer.\n<\/p>\n<p>\n\u201cWe look forward to sharing new data at WCLC that demonstrate the utility of our liquid biopsy tests and datasets to create more accurate tumor profiles and impact outcomes for lung cancer patients around the world,\u201d said Helmy Eltoukhy, Guardant Health co-CEO. \u201cThe data from retrospective and real-world analyses will show how blood-based tests provide critical insights into tumor evolution and treatment resistance throughout each lung cancer patient\u2019s treatment journey and contribute more broadly to further developing the field of thoracic oncology.\u201d\n<\/p>\n<p>\n<b>Full List of Presentations:<\/b>\n<\/p>\n<p>\n<b>Guardant360<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nClinical and molecular profile of patients with non-small cell lung cancer (NSCLC) with incidental pathogenic germline variants detected in cfDNA (oral)\n<\/li>\n<li>\nPatterns of KEAP1 genomic co-alterations in advanced lung cancer as identified by plasma-based genotyping (e-poster)\n<\/li>\n<li>\nGermline HRR mutations in metastatic NSCLC and impact on progression-free survival: A single-center retrospective study (e-poster)\n<\/li>\n<li>\nTargetable alterations in non-small cell lung cancer according to age and sex (e-poster)\n<\/li>\n<li>\nLiquid biopsies first to make treatment decisions in patients with metastatic non-small cell lung cancer (NSCLC) (e-poster)\n<\/li>\n<li>\nLandscape of EGFR extracellular domain mutations in advanced non-small cell lung carcinoma (e-poster)\n<\/li>\n<li>\nThe patient impact of liquid biopsy \u2013 health-related quality of life in patients undergoing liquid biopsy for advanced non-small cell lung cancer (e-poster)\n<\/li>\n<\/ul>\n<p>\n<b>GuardantINFORM<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nImpact of germline BRCA1\/2 alterations on EGFR mutant advanced non-small cell lung cancer outcomes (e-poster)\n<\/li>\n<li>\nReal-world landscape of EGFR C797X mutation as a resistance mechanism to osimertinib in non-small cell lung cancer (oral)\n<\/li>\n<\/ul>\n<p>\n<b>GuardantOMNI<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDurvalumab + olaparib vs. durvalumab alone as maintenance therapy in metastatic NSCLC: Outcomes from the phase 2 ORION study (poster)\n<\/li>\n<\/ul>\n<p>\n<b>About Guardant Health<\/b>\n<\/p>\n<p>\nGuardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360\u00ae, Guardant360 CDx, Guardant360 TissueNext\u2122, Guardant360 Response\u2122, and GuardantOMNI\u00ae tests for advanced stage cancer patients, and Guardant Reveal\u2122 for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield<sup>\u2122<\/sup> test, aims to address the needs of individuals eligible for cancer screening. For more information, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fguardanthealth.com%2F&amp;esheet=52803540&amp;newsitemid=20220805005190&amp;lan=en-US&amp;anchor=guardanthealth.com&amp;index=1&amp;md5=42f31c24f5c8e66b41b8c67d20dc52ca\" rel=\"nofollow noopener\" shape=\"rect\">guardanthealth.com<\/a> and follow the company on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fguardanthealth&amp;esheet=52803540&amp;newsitemid=20220805005190&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=b518a14ae523d4d6dff75a5fbbf0fd18\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FGuardantHealth&amp;esheet=52803540&amp;newsitemid=20220805005190&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=4738d2f74a45625a558de08a23dd90e4\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\nThis press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health\u2019s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health\u2019s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operation\u201d and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2021 and in its other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health\u2019s views as of any date subsequent to the date of this press release.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor Contact:<\/b><br \/>Alex Kleban<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;&#111;:i&#x6e;&#x76;&#x65;&#x73;&#116;&#111;rs&#x40;&#x67;&#x75;&#x61;&#114;&#100;an&#x74;&#x68;&#x65;&#x61;&#108;&#116;&#104;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">inve&#115;&#116;&#111;&#114;&#115;&#x40;&#x67;&#x75;&#x61;&#x72;&#x64;&#x61;nthe&#97;&#108;&#116;&#104;&#46;&#x63;&#x6f;&#x6d;<\/a><br \/>+1 657-254-5417\n<\/p>\n<p>\n<b>Media Contact:<\/b><br \/>Michele Rest<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x70;&#114;&#x65;&#115;&#x73;&#64;&#x67;&#117;&#x61;&#114;&#x64;&#97;&#x6e;&#116;&#x68;&#101;&#x61;&#108;&#x74;&#104;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x70;&#x72;&#x65;&#x73;&#x73;&#x40;&#x67;&#x75;&#x61;&#x72;&#x64;&#x61;&#x6e;&#x74;&#x68;&#x65;&#x61;&#x6c;&#x74;&#x68;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>+1 215-910-2138\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46983","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T13:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer\",\"datePublished\":\"2022-08-05T13:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/\"},\"wordCount\":799,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005190\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/\",\"name\":\"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005190\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"datePublished\":\"2022-08-05T13:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005190\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220805005190\\\/en\\\/1330243\\\/21\\\/GuardantHealthLogo_TM_RGB-2C.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend","og_description":"Presentations to highlight role of liquid biopsy tests and real-world data in identifying resistance mechanisms to therapy, demonstrating impact of specific mutations on treatment efficacy, and informing therapeutic strategies in lung cancer PALO ALTO, Calif.&#8211;(BUSINESS WIRE)&#8211;Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that studies utilizing its portfolio of blood tests ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-05T13:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer","datePublished":"2022-08-05T13:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/"},"wordCount":799,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/","url":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/","name":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","datePublished":"2022-08-05T13:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220805005190\/en\/1330243\/21\/GuardantHealthLogo_TM_RGB-2C.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/guardant-health-announces-new-data-from-its-portfolio-of-blood-tests-and-guardantinform-real-world-clinical-genomic-platform-at-iaslc-2022-world-conference-on-lung-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM\u2122 Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46983","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46983"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46983\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46983"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46983"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46983"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}